Our Science

Mechanism-driven platform advancing PSA-activated, tumor-selective prodrugs for prostate cancer.

Molecular structures and analytical dashboard — oncology drug discovery platform
From target biology to data-driven lead prioritization — Innovex Discovery platform workflow
PSA-activated prodrug cleavage event releasing payload near tumor cells

PSA-Activated Prodrugs, Precisely Targeted

Innovex Discovery engineers PSA-activated prodrugs that remain inactive in circulation and healthy tissue, then release cytotoxic payloads where prostate-specific antigen is abundant. This tumor-selective strategy aims to enhance efficacy while reducing systemic toxicity in preclinical models.

Explore the Lead Program